Literature DB >> 30652593

Automated Renal Cancer Grading Using Nuclear Pleomorphic Patterns.

Daniel Aitor Holdbrook1, Malay Singh1, Yukti Choudhury1, Emarene Mationg Kalaw1, Valerie Koh1, Hui Shan Tan1, Ravindran Kanesvaran1, Puay Hoon Tan1, John Yuen Shyi Peng1, Min-Han Tan1, Hwee Kuan Lee1.   

Abstract

PURPOSE: Nuclear pleomorphic patterns are essential for Fuhrman grading of clear cell renal cell carcinoma (ccRCC). Manual observation of renal histopathologic slides may lead to subjective and inconsistent assessment between pathologists. An automated, image-based system that classifies ccRCC slides by quantifying nuclear pleomorphic patterns in an objective and consistent interpretable fashion can aid pathologists in histopathologic assessment.
METHODS: In the current study, histopathologic tissue slides of 59 patients with ccRCC who underwent surgery at Singapore General Hospital were assembled retrospectively. An automated image classification pipeline detects and analyzes prominent nucleoli in ccRCC images to classify them as either low (Fuhrman grade 1 and 2) or high (Fuhrman grade 3 and 4). The pipeline uses machine learning and image pixel intensity-based feature extraction techniques for nuclear analysis. We trained classification systems that concurrently analyze different permutations of multiple prominent nucleoli image patches.
RESULTS: Given the parameters for feature combination and extraction, we present experimental results across various configurations for the classification of a given ccRCC histopathologic image. We also demonstrate that the image score used by the pipeline, termed fraction value, is correlated ( R = 0.59) with an existing multigene assay-based scoring system that has previously been demonstrated to be a strong indicator of prognosis in patients with ccRCC.
CONCLUSION: The current method provides an objective and fully automated way by which to process pathologic slides. The correlation study with a multigene assay-based scoring system also allows us to provide quantitative interpretation for already established nuclear pleomorphic patterns in ccRCC. This method can be extended to other cancers whose corresponding grading systems use nuclear pattern information.

Entities:  

Mesh:

Year:  2018        PMID: 30652593     DOI: 10.1200/CCI.17.00100

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  6 in total

Review 1.  Current and future applications of machine and deep learning in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer.

Authors:  Rodrigo Suarez-Ibarrola; Simon Hein; Gerd Reis; Christian Gratzke; Arkadiusz Miernik
Journal:  World J Urol       Date:  2019-11-05       Impact factor: 4.226

Review 2.  Can artificial intelligence overtake human intelligence on the bumpy road towards glioma therapy?

Authors:  Precilla S Daisy; T S Anitha
Journal:  Med Oncol       Date:  2021-04-03       Impact factor: 3.064

3.  Early experience with Watson for Oncology: a clinical decision-support system for prostate cancer treatment recommendations.

Authors:  Seong Hyeon Yu; Myung Soo Kim; Ho Seok Chung; Eu Chang Hwang; Seung Il Jung; Taek Won Kang; Dongdeuk Kwon
Journal:  World J Urol       Date:  2020-04-25       Impact factor: 4.226

4.  Deep learning based prediction of prognosis in nonmetastatic clear cell renal cell carcinoma.

Authors:  Seok-Soo Byun; Tak Sung Heo; Jeong Myeong Choi; Yeong Seok Jeong; Yu Seop Kim; Won Ki Lee; Chulho Kim
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 5.  Artificial intelligence for renal cancer: From imaging to histology and beyond.

Authors:  Karl-Friedrich Kowalewski; Luisa Egen; Chanel E Fischetti; Stefano Puliatti; Gomez Rivas Juan; Mark Taratkin; Rivero Belenchon Ines; Marie Angela Sidoti Abate; Julia Mühlbauer; Frederik Wessels; Enrico Checcucci; Giovanni Cacciamani
Journal:  Asian J Urol       Date:  2022-06-18

6.  Automated clear cell renal carcinoma grade classification with prognostic significance.

Authors:  Katherine Tian; Christopher A Rubadue; Douglas I Lin; Mitko Veta; Michael E Pyle; Humayun Irshad; Yujing J Heng
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.